Intercell, GSK To Develop, Commercialise Needle-Free Patch-Based Vaccines
Intercell and GlaxoSmithKline Biologicals (GSK) will form a strategic alliance to accelerate the development and commercialisation of needle-free, patch-based vaccines. The agreement will include Intercell’s candidate vaccine for
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.